# Clozapine for Patients With Intellectual Disabilities: A Case Series Illustrating the Clinical Potentials

**Authors:** Magnus Roland Balleby, Jacob Bentsen, Jimmi Nielsen

PMC · DOI: 10.1155/crps/9592396 · 2025-10-28

## TL;DR

This paper explores the use of clozapine to treat challenging behaviors in patients with intellectual disabilities when other treatments fail.

## Contribution

The study presents five case scenarios showing clozapine's potential for treatment-resistant behaviors in intellectual disability.

## Key findings

- Four out of five patients showed significant reduction in challenging behaviors with clozapine.
- Two patients experienced reduced psychotic or affective symptoms.
- Side effects were mild and manageable with point-of-care monitoring.

## Abstract

Challenging behaviours (CBs) are common in patients with intellectual disabilities (IDs) and diagnosing an underlying primary psychiatric disorder is often difficult. Even though many respond to non-pharmacological or pharmacological interventions persistent aggressive and self-injurious behaviour occur and no treatment-resistant guideline exists. We aim to present clinical scenarios regarding patients with ID and persistent CB with or without a primary psychiatric disorder where clozapine could be considered.

We present five patients with ID with persistent CB with or without a primary psychiatric disorder treated with clozapine. Four of the five patients responded well to clozapine treatment with markedly decreased CB, and two patients had reduced psychotic- or affective symptoms. Side-effects were mild and manageable. Haematological monitoring was performed with a point-of-care (POC) test device.

We show that clozapine can be efficacious in persistent CB and/or treatment-resistant psychiatric symptoms in patients with ID. Monitoring and managing side-effects were possible.

We suggest that clozapine should be considered in patients with ID regardless of a primary psychiatric disorder when CB does not respond to non-pharmacological and first line pharmacological treatment. It is possible to monitor and manage side-effects with a systematic approach including the use of POC testing.

## Linked entities

- **Chemicals:** clozapine (PubChem CID 135398737)
- **Diseases:** intellectual disabilities (MONDO:0001071)

## Full-text entities

- **Diseases:** psychiatric disorder (MESH:D001523), IDs (MESH:D008607), aggressive (MESH:D010554), ID (MESH:C537985), psychotic- or affective symptoms (MESH:D000341)
- **Chemicals:** CB (-), Clozapine (MESH:D003024)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12585794